Establishment Labs Expands Motiva Implant Portfolio with FDA Approval of 28 New Sizes
Event summary
- FDA approved 28 new sizes for Motiva SmoothSilk Round and Ergonomix breast implants, including sizes as small as 105 cc.
- New sizes expand options across Mini, Demi, and Full profiles for both product lines.
- Products will be commercially available before the end of 2026.
- CEO Peter Caldini cites growing demand for smaller, natural-looking breast implants.
The big picture
The FDA approval aligns with the growing trend toward smaller, more natural breast augmentation procedures. Establishment Labs is positioning itself to capture market share by offering a broader range of implant sizes, catering to both traditional and minimally invasive procedures. The expansion of the Motiva portfolio could strengthen the company's competitive position in the global breast aesthetics market.
What we're watching
- Market Share Gains
- How the expanded size range will accelerate Establishment Labs' market share gains in the breast aesthetics and reconstruction segment.
- Surgeon Adoption
- Whether the additional sizes will drive higher adoption rates among plastic surgeons already using Motiva implants.
- Revenue Impact
- The pace at which the new product offerings will contribute to Establishment Labs' revenue growth.
Related topics